Dr. Hylek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
801 Massachusetts Ave
Crosstown 6C
Boston, MA 02118Phone+1 617-414-5951Fax+1 617-414-9201
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 1988 - 1991
University of Pittsburgh School of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1993 - 2026
Awards, Honors, & Recognition
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016
- Boston Magazine Castle Connolly, 2011-2013
Publications & Presentations
PubMed
- Stroke-bleeding risk score pairings within individuals in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry.Max J Jason, Lucas N Marzec, Jonathan P Piccini, Peter Shrader, Karen S Pieper
International Journal of Cardiology. 2025-02-15 - Use of continuous cardiac monitoring to assess the influence of atrial fibrillation burden and patterns on patient symptoms and healthcare utilization: The DEFINE AFib...Dhanunjaya R Lakkireddy, Andrea M Russo, Elaine M Hylek, Suneet Mittal, James Peacock
Heart Rhythm O2. 2024-12-01 - Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification.Jonathan P Piccini, Evan J Stanelle, Cody C Johnson, Elaine M Hylek, Rahul Kanwar
Circulation. Arrhythmia and Electrophysiology. 2024-11-01
Journal Articles
- Treatment Persistence in Atrial Fibrillation: The Next Major HurdleElaine (Kozlowski) Hylek, MD, Thrombosis and Haemostasis
- Original Investigation Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients with Atrial Fibrillation: An ARISTOTLE SubstudyJohn H Alexander, Elaine M Hylek, ScienceDirect
- Choosing a Particular Oral Anticoagulant and Dose for Stroke Prevention in Individual Patients with Non-Valvular Atrial Fibrillation: Part 1Jonathan L Halperin, Elaine M Hylek, Michael D Ezekowitz, James Aisenberg, European Heart Journal
Authored Content
- Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisJuly 2017
Press Mentions
Catheter-Directed Fibrinolysis Safe in Intermediate-High-Risk Pulmonary EmbolismDecember 16th, 2022- Hints of Benefit with Catheter-Directed Thrombolysis in Intermediate/High-Risk PEOctober 19th, 2022
- Catheter-Directed Thrombolysis Promising for Intermediate-Risk Pulmonary EmbolismOctober 19th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
